Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results
May 03, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc. Rhythm Pharmaceuticals, Inc. First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter – Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at up to nine months in HET obesity, as well as weight loss data in adults and BMI-Z reductions in adolescents with Bardet-Biedl syndrome Delivered proof-of-concept data from Phase 2 Basket Study in HET POMC, PCSK1 or LEPR deficiencies, and obesity due to SRC1 and SH2B1 deficiencies Closed $172.5 million public offering and sold Priority Review Voucher for $100 million, providing additional funding to advance continued development of setmelanotide